Suzanne Lemler

2.2k total citations · 1 hit paper
11 papers, 1.6k citations indexed

About

Suzanne Lemler is a scholar working on Genetics, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Suzanne Lemler has authored 11 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 4 papers in Oncology and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Suzanne Lemler's work include Estrogen and related hormone effects (6 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Menopause: Health Impacts and Treatments (3 papers). Suzanne Lemler is often cited by papers focused on Estrogen and related hormone effects (6 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Menopause: Health Impacts and Treatments (3 papers). Suzanne Lemler collaborates with scholars based in United States, Germany and South Korea. Suzanne Lemler's co-authors include David A. Flockhart, Anna Maria Storniolo, Jill A. Hayden, Vered Stearns, Daniel F. Hayes, Anne Nguyen, Todd C. Skaar, Zeruesenay Desta, N. Lynn Henry and Lang Li and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Suzanne Lemler

11 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

2005 681 citations Yan Jin, Zeruesenay Desta et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suzanne Lemler United States	11	729	664	433	283	239	11	1.6k
Thomas P. Ahern United States	28	494 0.7×	641 1.0×	220 0.5×	913 3.2×	461 1.9×	108	2.5k
Antonio González‐Pérez Spain	27	457 0.6×	275 0.4×	102 0.2×	211 0.7×	366 1.5×	69	2.8k
Qun‐Ying Yue Sweden	19	126 0.2×	328 0.5×	835 1.9×	63 0.2×	325 1.4×	35	1.6k
JS Leeder United States	10	245 0.3×	451 0.7×	1.3k 3.1×	27 0.1×	281 1.2×	10	2.3k
Mats Hidestrand United States	26	182 0.2×	439 0.7×	876 2.0×	127 0.4×	549 2.3×	40	1.8k
Ernst‐Ulrich Griese Germany	19	99 0.1×	472 0.7×	895 2.1×	48 0.2×	334 1.4×	29	1.6k
Hiroshi Takane Japan	23	57 0.1×	675 1.0×	242 0.6×	114 0.4×	468 2.0×	71	1.8k
Brendan McAdam Ireland	12	301 0.4×	92 0.1×	192 0.4×	71 0.3×	200 0.8×	26	2.1k
Alberto Chiappe Switzerland	7	66 0.1×	160 0.2×	454 1.0×	124 0.4×	248 1.0×	8	960
Nada Božina Croatia	23	138 0.2×	423 0.6×	482 1.1×	56 0.2×	242 1.0×	86	1.5k

Countries citing papers authored by Suzanne Lemler

Since Specialization

Citations

This map shows the geographic impact of Suzanne Lemler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Lemler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Lemler more than expected).

Fields of papers citing papers by Suzanne Lemler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Lemler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Lemler. The network helps show where Suzanne Lemler may publish in the future.

Co-authorship network of co-authors of Suzanne Lemler

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Lemler. A scholar is included among the top collaborators of Suzanne Lemler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Lemler. Suzanne Lemler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Cho, Doo‐Yeoun, Suzanne Lemler, Todd C. Skaar, et al.. (2015). Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. Drug Metabolism and Pharmacokinetics. 31(2). 107–116. 16 indexed citations

Henry, N. Lynn, Faouzi Azzouz, Zereunesay Desta, et al.. (2012). Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer. Journal of Clinical Oncology. 30(9). 936–942. 284 indexed citations

Rand, Kevin L., Julie L. Otte, David A. Flockhart, et al.. (2010). Modeling hot flushes and quality of life in breast cancer survivors. Climacteric. 14(1). 171–180. 45 indexed citations

Otte, Julie L., David A. Flockhart, Daniel F. Hayes, et al.. (2009). Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy. Menopause The Journal of The North American Menopause Society. 16(4). 653–659. 20 indexed citations

Desta, Zeruesenay, Anil Modak, Phuong D. Nguyen, et al.. (2009). Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C]Pantoprazole Breath Test. Journal of Pharmacology and Experimental Therapeutics. 329(1). 297–305. 32 indexed citations

Jin, Yan, Daniel F. Hayes, Lang Li, et al.. (2008). Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen Therapy. Journal of Clinical Oncology. 26(36). 5849–5854. 37 indexed citations

Nguyen, Anne, Vered Stearns, Anne F. Schott, et al.. (2007). Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen. Clinical Pharmacology & Therapeutics. 83(5). 702–710. 31 indexed citations

Schneider, Bryan P., Milan Radovich, George W. Sledge, et al.. (2007). Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Research and Treatment. 111(1). 157–163. 100 indexed citations

Henry, N. Lynn, Jon T. Giles, Dennis C. Ang, et al.. (2007). Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Research and Treatment. 111(2). 365–372. 187 indexed citations

10.

Jin, Yan, Zeruesenay Desta, Vered Stearns, et al.. (2005). CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. JNCI Journal of the National Cancer Institute. 97(1). 30–39. 681 indexed citations breakdown →

11.

Rex, Douglas K., Annie Lee, E. W. Strahl, et al.. (2002). Safety of propofol administered by registered nurses with gastroenterologist supervision in 2000 endoscopic cases. The American Journal of Gastroenterology. 97(5). 1159–1163. 178 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact